Joint Pain Injections Market – By Injection Type, By Joint Type, By End Use - Global Forecast, 2026 - 2035

Based on the injection type, the global market is segmented into hyaluronic acid injections, corticosteroid injections, platelet-rich plasma injections, and other injection types. The hyaluronic acid segment dominated the market and was valued at USD 3.9 billion in 2025.
 

• The hyaluronic acid segment accounts for a substantial share of the joint pain injections market owing to its proven effectiveness in viscosupplementation therapy for osteoarthritis.
   
• Hyaluronic acid injections help restore joint lubrication, reduce friction, and improve mobility, making them a preferred non-surgical treatment option for mild to moderate joint degeneration.
   
• Their strong clinical acceptance, favorable safety profile, and widespread availability across hospital and outpatient settings, combined with the growing prevalence of osteoarthritis, continue to reinforce the segment’s dominant market position.
   
• On the other hand, the platelet rich plasma injections segment is expected to grow at a CAGR of 8.4%, driven by rising demand for regenerative therapies that address the underlying causes of joint degeneration rather than only providing symptomatic relief.
   
• Proven efficacy of PRP coupled with growing awareness and adoption among the orthopedic specialists and sports medicine practitioners is accelerating adoption globally and expanding its use across multiple joints, thereby fueling rapid segment growth.
   

Based on the joint type, the global joint pain injections market is classified into knee, shoulder and elbow, ankle and hip, and other joint types. The knee segment accounted for the highest market share in 2025 and is expected to reach USD 9.6 billion by 2035.
 

• The growth of this segment can be attributed mainly to the rising incidence of knee osteoarthritis globally, driven by aging populations, increasing incidence of obesity, sedentary lifestyle, and growing cases of metabolic and systemic conditions.
   
• For instance, according to the National Institutes of Health, worldwide, about 13% of women and 10% of men aged 60 years and above have symptomatic knee OA. The figure rises to 40% for people over 70 years, highlighting a significant patient pool, thereby driving sustained market growth.
   
• Further, the dominance of the knee segment is supported by the availability of multiple injectable therapies, including hyaluronic acid, corticosteroids, and platelet-rich plasma (PRP). These therapy options enhance adoption and solidify the knee segment’s leading position.
   
• On the other hand, the shoulder and elbow segment is anticipated to witness growth at a CAGR of 7.4% over the forecast period, driven by the rising incidence of sports-related injuries, rotator cuff tears, and repetitive strain disorders, particularly among active adults and aging populations.
   
• Additionally, improved diagnostics, growing awareness and advancements in minimally invasive and non-surgical treatment options are some of the factors supporting the sustained growth in this segment.
   

Based on end use, the global joint pain injections market is classified into hospitals, orthopedic/pain clinics, ambulatory surgical centers, and other end users. The hospitals segment held the highest market share of 56.6% in 2025, largely due to the availability of advanced medical infrastructure and specialized facilities in hospital settings.
 

The orthopedic/pain clinics segment, on the other hand, is expected to witness significant growth at a CAGR of 8.2% over the forecast period. The growth is driven by the increasing preference for specialized, outpatient-based care for joint pain management. These clinics offer targeted expertise, shorter waiting times, and personalized treatment approaches, making them an attractive alternative to hospital settings.
 

• Hospitals are equipped with advanced diagnostic imaging tools, orthopedic and rheumatology departments, and pain management units, enabling accurate assessment and effective administration of joint pain injections, thereby driving the growth of the segment.
   
• Another factor contributing to the dominance of hospitals is the high patient trust associated with these settings. Patients often prefer hospitals for procedures involving injections due to the perception of greater safety, access to emergency care, and the ability to manage potential complications promptly, thereby strengthening the segment’s market position.
   

North America Joint Pain Injections Market

The North America market dominated the global joint pain injections market with a market share of 47.1% in 2025.
 

• North America holds a dominant share of the global market, supported by a large patient population with a high prevalence of osteoarthritis and other joint disorders. For instance, according to the Centers for Disease Control and Prevention, OA affects over 32.5 million U.S. adults.
   
• In addition, advanced healthcare infrastructure, widespread adoption of innovative and biologic injection therapies, and favorable reimbursement policies contribute significantly to the region’s leadership in market revenue.
   
• Additionally, high healthcare expenditure, strong awareness of non-surgical treatment options among both patients and clinicians, and the presence of key market players further reinforce North America’s position as the largest regional market.
   

The U.S. joint pain injections market was valued at USD 2.2 billion and USD 2.4 billion in 2022 and 2023, respectively. The market size reached USD 2.6 billion in 2025, growing from USD 2.5 billion in 2024.
 

• This growth trajectory is underpinned by the high and increasing prevalence of joint-related conditions in the U.S. adult population.
   
• For instance, according to data from the Centers for Disease Control and Prevention (CDC), approximately 18.9% of U.S. adults, that is, almost 1 in 5, had been diagnosed with arthritis in 2022, and the prevalence rises sharply with age, such that more than half of adults aged 75 and older experience arthritis.
   
• Given that arthritis and related musculoskeletal disorders are leading causes of chronic joint pain and functional limitation, this large patient base continues to drive sustained demand for joint pain injections.
   
• Further, continuous clinical research, rapid regulatory approvals, and strong physician preference for evidence-based injectable therapies have collectively reinforced the upward trajectory of the U.S. market.
   

Europe Joint Pain Injections Market

Europe market accounted for USD 1.5 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The rising prevalence of osteoarthritis and other degenerative joint disorders across the region’s aging population is a key factor driving regional market growth.
   
• Additionally, strong public healthcare systems and the widespread presence of orthopedic and rheumatology clinics play a key role in supporting the routine use of joint pain injection therapies.
   
• These healthcare frameworks allow for early diagnosis and timely access to minimally invasive pain management options, helping sustain consistent treatment adoption throughout the region.
   

Germany dominates the Europe joint pain injections market, showcasing strong growth potential.
 

• According to Statista, individuals aged 40–59 years formed the largest age cohort in 2024, totaling approximately 22.3 million people, while those aged 65 years and above accounted for nearly 19 million. These age groups face a higher risk of degenerative joint conditions, osteoarthritis, and chronic musculoskeletal pain, resulting in a steady and long-term demand for injection-based therapies.
   
• Beyond population dynamics, Germany’s advanced healthcare infrastructure further strengthens market growth.
   
• Broad access to orthopedic specialists, rheumatologists, and dedicated pain management services enables appropriate treatment selection and early intervention, accelerating the adoption of joint pain injections across both public and private healthcare settings.
   

Asia Pacific Joint Pain Injections Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.3% during the analysis timeframe.
 

• The growth can be majorly attributed to the rapidly expanding aging population and the rising prevalence of osteoarthritis and other degenerative joint disorders across key countries such as China, Japan, India, and South Korea.
   
• Additionally, increasing life expectancy, coupled with lifestyle changes and higher rates of obesity, has significantly elevated the burden of chronic joint pain in the region.
   
• For instance, according to WHO data, parts of the WHO South-East Asia Region report approximately 31% prevalence of overweight among adults, indicating a substantial share of the population is at increased risk of musculoskeletal strain and joint-related disorders, thereby expanding the addressable patient pool and the market for joint pain injection therapies.
   

India joint pain injections market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• Epidemiological evidence shows knee osteoarthritis prevalence in India to be around 22-39% of the population studied, indicating a high burden of degenerative joint pain at quite young ages. This high prevalence of knee osteoarthritis creates a significant patient pool requiring effective pain management interventions, making joint pain injections a critical treatment option.
   
• In addition to the high incidence of joint disorders, India’s rapidly aging population is contributing to the increasing demand for joint pain injections, thereby contributing to the market growth.
   
• Moreover, increasing awareness about minimally invasive treatments and technological innovations in joint pain injection options is also favoring market growth.
   

Latin American Joint Pain Injections Market

Brazil leads the Latin American market and is anticipated to witness significant growth during the analysis period.
 

• As per a research article, in 2023, the Brazilian public healthcare system spent an estimated USD 58 million on osteoarthritis, with knee osteoarthritis taking the major portion of these costs, highlighting the substantial clinical and economic burden of joint disease in the country.
   
• The rising prevalence of osteoarthritis, particularly among the aging population, together with increasing obesity rates and lifestyle-related risk factors, is driving the demand for effective, minimally invasive joint pain injection therapies.
   

Middle East and Africa Joint Pain Injections Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa region due to the expanding burden of osteoarthritis and chronic joint pain, especially among older adults.
 

• In Saudi Arabia, the prevalence of knee osteoarthritis sharply increases with age, affecting approximately 31% of adults aged 46–55 years and nearly 61% of those aged 66–75 years, indicating a large and rapidly growing patient pool for injectable therapies.
   
• This rising disease burden, coupled with increasing healthcare expenditure and expanding orthopedic care infrastructure, is driving broader adoption of intra-articular pain management solutions, including corticosteroids, hyaluronic acid, and emerging biologic injections.
   

Joint Pain Injections Market Share

The global market is characterized by a mix of established pharmaceutical giants and specialized biotech firms competing across corticosteroid, viscosupplementation (e.g., hyaluronic acid), and biologic injection segments. Leading companies such as Zimmer Biomet, Ferring, Pfizer, Sanofi, and Bioventus account for approximately 56.2% of the market share due to their established brands, broad product portfolios, and extensive global distribution channels.
 

Additionally, partnerships with academic institutions and licensing agreements for novel pipeline therapies are accelerating innovation in the joint pain injections market, particularly in the development of next-generation biologics and regenerative solutions for osteoarthritis and other joint disorders. Many companies are also increasing investments in research and development to create safer and more effective injectable treatments with longer-lasting efficacy and reduced side effects.
 

Joint Pain Injections Market Companies

Prominent players operating in the joint pain injections industry are as mentioned below:

• Anika Therapeutics
• Arthrex
• Bioventus
• Cipla
• Emcyte Corporation
• Ferring
• Lifecore Biomedical
• OrthogenRx
• Pacira BioSciences (Flexion)
• Pfizer
• Sanofi
• SEIKAGAKU CORPORATION
• Stryker Corporation
• Zimmer Biomet Holdings
   

Pfizer

The company accounts for approximately 23.5% of the global joint pain injections market through its portfolio of corticosteroid and hyaluronic acid injections, addressing critical needs in osteoarthritis and other musculoskeletal disorders. Pfizer has focused on product innovation and expanding minimally invasive treatment options, enhancing patient access to effective joint pain relief while leveraging its global distribution network to maintain market leadership.
 

Sanofi

The company is recognized for its viscosupplementation therapies, particularly hyaluronic acid–based injections such as Synvisc. The company has emphasized clinical research and development of longer-acting formulations and expanded treatment access for patients with knee osteoarthritis.
 

Zimmer Biomet

The company has built its reputation on orthopedic expertise and innovation in joint care, offering a range of injectable therapies targeting osteoarthritis and other musculoskeletal conditions. Zimmer Biomet continues to invest in research, strategic partnerships, and education for healthcare providers, driving adoption of its minimally invasive injection therapies and reinforcing its position as a trusted player in the market.
 

Joint Pain Injections Industry News

• In December 2025, Cipla Limited launched Ciplostem, an allogeneic mesenchymal stromal cell (MSC) therapy for Grade II and III knee osteoarthritis, approved by India’s DCGI and developed by Stempeutics Research. The therapy offers a disease-modifying option in orthobiologic treatment, marking a significant step in Cipla’s expansion into advanced joint care. This launch strengthened Cipla’s presence in the growing orthobiologics market and enhanced its portfolio in innovative musculoskeletal therapies.
   
• In December 2023, Bioventus entered a nationwide contract with Aetna Medicare Advantage plans for DUROLANE, a treatment for knee osteoarthritis. This strategic agreement enabled the company to expand its customer reach and increase revenue by gaining access to more than 3 million Aetna Medicare Advantage Plan members.
   
• In November 2022, Anika Therapeutics, Inc. announced that they had achieved the primary endpoint in Phase III Study for Cingal. This product is intended to provide long-lasting pain relief to treat the pain of knee osteoarthritis (OA). The firm is focusing on getting the U.S. FDA approval for Cingal and its launch. This successful trial helped the company to increase its R&D activities and gain a competitive edge over its peers.
   

The joint pain injections market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Injection Type

• Hyaluronic acid injections
• Corticosteroid injections
• Platelet rich plasma injections
• Other injection types

Market, By Joint Type

• Knee
• Shoulder and elbow
• Ankle and hip
• Other joint types

Market, By End Use

• Hospitals
• Orthopedic/pain clinics
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE